Find the Second Entrant Sweet Spot: A DrugPatentWatch Playbook for Generic and Biosimilar Strategy
The first generic filer gets the headlines. The second entrant often gets the margin. In the United States pharmaceutical market, […]
Drug Patents Are Breaking: How Personalized Medicine Is Exposing the Cracks
The pharmaceutical patent system was designed for a different drug. A small molecule, synthesized in a lab, dosed the same
Drug Patents Are Breaking: How Personalized Medicine Is Exposing the Cracks Read Post »
Ditch the Market Researcher: Why a Patent Analyst Suite Is the Pharma Competitive Intelligence Tool You Actually Need
Quick Summary: Traditional pharmaceutical market research tells you what happened yesterday. A patent analyst suite tells you what will happen
Reverse Engineer a Competitor’s Drug Pipeline Using Patent Filings
A competitor’s pipeline is not a secret. It is a public record, filed in tranches at the USPTO, EPO, and
Reverse Engineer a Competitor’s Drug Pipeline Using Patent Filings Read Post »
The Cannabinoid Patent Gold Rush: What Pharma IP Veterans Know That Cannabis Companies Don’t
GW Pharmaceuticals spent roughly two decades and hundreds of millions of dollars turning cannabis extracts into regulated pharmaceuticals. When Jazz
Who Owns the AI-Discovered Drug? The Pharmaceutical Patent Ownership Crisis Explained
The pharmaceutical industry spent the last decade automating drug discovery. Billions went into generative chemistry platforms, phenomic screening systems, and
Who Owns the AI-Discovered Drug? The Pharmaceutical Patent Ownership Crisis Explained Read Post »
Rare Disease Patents: Why Challengers Need a Different Playbook
The standard Paragraph IV playbook was written for atorvastatin and metformin, not for drugs prescribed to 800 patients nationwide. When
Rare Disease Patents: Why Challengers Need a Different Playbook Read Post »
Diagnostic Patents: The IP Frontier That Pharma Vendors Can No Longer Ignore
The pharmaceutical vendor ecosystem — CROs, CDMOs, biomarker platform providers, data analytics firms, and laboratory services companies — has spent
Diagnostic Patents: The IP Frontier That Pharma Vendors Can No Longer Ignore Read Post »
Biologic Patent Tracking: What to Do When the Purple Book Fails You
The FDA’s Purple Book is supposed to be the authoritative public registry for biologic drug patents in the United States.
Biologic Patent Tracking: What to Do When the Purple Book Fails You Read Post »
